Company reported ZILRETTA® ( triamcinolone acetonide extended-release injectable suspension) net sales of $15.5 million in second quarter 2020 Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021 BURLINGTON, Mass. , Aug.
BURLINGTON, Mass. , July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business highlights after the close of the U.S. financial markets on Wednesday, August 5, 2020 .
Company reported ZILRETTA ( triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarter Demand for ZILRETTA from healthcare providers increased month-over-month throughout the second quarter with total demand in line with the first
BURLINGTON, Mass. , June 16, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference . The
BURLINGTON, Mass. , May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceeds from this offering are expected to be
BURLINGTON, Mass. , May 20, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to an
BURLINGTON, Mass. , May 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2020 Virtual Global Healthcare Conference
Company reported ZILRETTA ® ( triamcinolone acetonide extended-release injectable suspension) net sales of $20.1 million in first quarter 2020 Flexion implementing broad cost savings initiatives; guiding to total operating expenses in the range of $167 million to $177 million for 2020 Phase 2
FX201 preclinical in vivo data in a rodent model of OA showed slowing of disease progression 12 weeks post-surgery, persistence of the vector genome in the joint for at least 92 days with absence of systemic distribution, and a favorable safety profile Productivity, purification yields, and product
An analysis of prospective radiographic assessments of 305 patients showed no adverse joint effects following treatment with ZILRETTA® Analysis of patient mobility indicated patients treated with ZILRETTA walked more steps per day in concert with pain reduction Survey of 1,000 patients with
